Drug development for ischemic stroke is challenging as evidenced by the paucity of therapeutics that have advanced beyond a phase III trial. There are many reasons for this lack of clinical ...
With the right metrics, you can increase the return on both. by Jim Stengel, Cait Lamberton and Ken Favaro Over the past 20 years, performance marketing has become the dominant approach companies use ...
Troy Segal is an editor and writer. She has 20+ years of experience covering personal finance, wealth management, and business news. Thomas J Catalano is a CFP and Registered Investment Adviser with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results